aims assessed montelukast formoterol provides additive effects asthmatics controlled inhaled corticosteroids studying patients considered genetically susceptible regulation subsensitivity expressed homozygous beta2receptor genotype methods mild moderate persistent asthmatics received montelukast NUMBER mg daily formoterol NUMBER micro g twice daily NUMBER weeks separated placebo washout doubledummy randomized crossover design bronchoprotection adenosine monophosphate amp challenge primary endpoint spirometry blood eosinophils measured trough placebo doses results amp pc20vs placebo sustained significant p NUMBER doubling dilution improvements following NUMBER NUMBER ci NUMBER NUMBER NUMBER NUMBER ci NUMBER NUMBER doses montelukast following NUMBER NUMBER ci NUMBER NUMBER NUMBER NUMBER ci NUMBER doses formoterol blood eosinophils x NUMBER significantly p NUMBER suppressed dose montelukast NUMBER ci NUMBER compared placebo formoterol exhibited nonsignificant rise NUMBER NUMBER ci NUMBER treatment significantly improved fev1 pef NUMBER weeks conclusions genetically susceptible patients homozygous genotype montelukast formoterol conferred sustained properties addition inhaled corticosteroid dissociated changes lung function NUMBER weeks assessing lung function miss potentially beneficial effects montelukast used therapy beta2 receptor glycine NUMBER corticosteroid treated NUMBER week run double blind NUMBER l NUMBER NUMBER NUMBER NUMBER fef25 NUMBER glycine NUMBER anti inflammatory anti inflammatory add